Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models

American Journal of Epidemiology

Volumn 158, Issue 7, 2003, Pages 687-694

  Cole, Stephen R ^a   Hernán, Miguel A ^b   Robins, James M ^b   Anastos, Kathryn ^c   Chmiel, Joan ^d   Detels, Roger ^e   Ervin, Carolyn ^f   Feldman, Joseph ^g   Greenblatt, Ruth ^h   Kingsley, Lawrence ⁱ   Lai, Shenghan ^a   Young, Mary ^j   Cohen, Mardge ^k   Muñoz, Alvaro ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^j GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^k Jr Hospital of Cook County   (United States)

more..

Author keywords

Acquired immunodeficiency syndrome; Antiretroviral therapy; Causality; Confounding factors (epidemiology); Highly active

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PROBABILITY; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT INDICATION; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CONFOUNDING FACTORS (EPIDEMIOLOGY); DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MODELS, STATISTICAL; OBSERVATION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RNA; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 0141620176     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwg206     Document Type: Article

References (31)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33.
2. Muñoz A, Gange SJ, Jacobson LP. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS 2000;14:754-6.
3. Phillips AN, Grabar S, Tassie JM, et al. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999;13:2075-82.
4. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983;2:267-71.
5. Ahdieh L, Gange SJ, Greenblatt R, et al. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol 2000;152:923-33.
6. Robins JM. Structural nested failure time models. In: Armitage P, Colton T, eds. Encyclopedia of biostatistics. Chichester, United Kingdom: John Wiley and Sons, 1998:4372-89.
7. Robins J. A graphical approach to the identification and estimation of causal parameters in mortality studies with sustained exposure periods. J Chronic Dis 1987;40(suppl):139S-61S.
8. Robins JM. Marginal structural models. In: 1997 proceedings of the American Statistical Association, Section on Bayesian Statistical Science. Alexandria, VA: American Statistical Association, 1998:1-10.
9. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126:310-18.
10. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998;9:117-25.
11. Panel on Clinical Practices for Treatment of HIV Infection, US Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: AIDSinfo [formerly HIV/AIDS Treatment Information Service], National Institutes of Health, 2000. (World Wide Web URL: http://www.aidsinfo.nih.gov).
12. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41:1-19.
13. Hessol NA, Schwarcz S, Ameli N, et al. Accuracy of self-reports of acquired immunodeficiency syndrome and acquired immunodeficiency syndrome-related conditions in women. Am J Epidemiol 2001;153:1128-33.
14. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000;11:561-70.
15. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the joint causal effect of non-randomized treatments. J Am Stat Assoc 2001;96:440-8.
16. D'Agostino RB, Lee ML, Belanger AJ, et al. Relation of pooled logistic regression to time dependent Cox regression analysis: The Framingham Heart Study. Stat Med 1990;9:1501-15.
17. Horvitz DG, Thompson DJ. A generalization of sampling without replacement from a finite universe. J Am Stat Assoc 1952;47:663-85.
18. White HA. Maximum likelihood estimation of misspecified models. Econometrica 1982;50:1-25.
19. Pierce DA. The asymptotic effect of substituting estimators for parameters in certain types of statistics. Ann Stat 1982;10:475-8.
20. Robins JM, Rotnitzky A, Zhao LP. Estimation of regression coefficients when some regressors are not always observed. J Am Stat Assoc 1994;89:846-6.
21. Altman DG, De Stavola BL. Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med 1994;13:301-41.
22. Cole SR, Hernán MA. Fallibility in estimating direct effects. Int J Epidemiol 2002;31:163-5.
23. Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology 1992;3:143-55.
24. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998;280:1497-503.
25. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000;29:722-9.
26. Jacobson LP, Li R, Phair J, et al. Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression. Am J Epidemiol 2002;155:760-70.
27. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77.
28. Anastos K, Barron Y, Miotti P, et al. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med 2002;162:1973-80.
29. Cole SR, Li R, Anastos K, et al. Lead-time adjustment in cohort studies: evaluating when to initiate therapy. (Abstract TuOrB1143). Abstracts of the XIV International AIDS Conference, Barcelona, Spain, July 7-12, 2002. (World Wide Web URL: http://www.aids2002.com).
30. Greenland S, Robins JM. Confounding and misclassification. Am J Epidemiol 1985;122:495-506.
31. Maldonado G, Greenland S. Estimating causal effects. Int J Epidemiol 2002;31:422-38.